| |
|
|
| |
| 投稿时间： 2015-05-28 最后修改时间： 2015-06-20 摘要点击次数: 2857 全文下载次数: 1645 |
| |
| 引用本文：石光, 刘芳瑜.我国生物医药产业发展的现状与对策[J].中国卫生政策研究,2016,9(3):16-19 |
|
| 石光, 刘芳瑜 |
| 中国农工民主党中央研究室 北京 100011 |
| |
|
| | 摘要:目的:系统梳理目前制约我国生物医药产业发展的政策瓶颈,并提出政策建议。方法:检索并系统复习国内外文献,对国内代表性生物医药企业开展典型调查,并对企业家和政策制定者进行定性访谈。结果:生物医药产业是中国应对经济新常态的具有巨大发展前景的新兴产业;可通过建立生物医药产业创新平台、加强南南合作等加快生物医药产业发展;医保报销目录更新滞后和药品集中招标采购政策不完善严重影响了医药产业创新和发展。结论:通过建立新药注册审批通道加快审批、鼓励生物创新药研发政策和医保报销制度,促进生物医药产业发展。 | |
|
|
关键词:生物医药产业 健康服务业 政策瓶颈 研发 创新药
|
| |
| The status quo and strategies on biotechnological medicine industry development in China |
| SHI Guang, LIU Fang-yu |
| Department of Research, Central Committee of Peasants and Workers Party, Beijing 100011, China |
| |
|
| | Abstract:Objective:To analyze the policy obstacles which hinders the development of the biomedical industry in China, and put forward the policy recommendation and strategies. Methods:To review the relevant papers on biotechnological medicine industry based on key-words screening and survey the biotechnological enterprises and interview the entrepreneurs and policy makers. Results:The biotechnological medicine industry is a promising industry with potential development space, especially dealing with the current new normal of economic development in China. The biotechnological medicine industry can be promoted through the creation of industry development platform, the cooperation among the Southern Countries. The slow updating of the reimbursement list for the Basic Medical Insurance System and the loopholes of the Centralized Biding and Purchase Policy on Medicine have negative impacts on the biotechnological medicine industry. Conclusion:It is suggested that the fast track on the registration on biotechnological innovative medicine should be established and the encouraging policy on research and development on biotechnological innovative medicine and the reimbursement policy for the Basic Medical Insurance System should be developed. | |
|
|
|
|
